Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine in patients with weak or absent esophageal peristalsis
2019-002187-26Phase 3Completed
- Sponsor
- KU Leuven
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of neostigmine in esophageal dysmotility and dysphagia, sponsored by KU Leuven. Primary endpoint: Mean change of distal contractile integral for 5 ml liquid boluses. Started Aug 2019; status: completed.
02
Drugs
neostigmine
03
Conditions
esophageal dysmotilitydysphagia
Beyond the preview
Go deeper on 2019-002187-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002187-26.